oral glp-1 analogues Receptor Signaling and Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects Development of an orally delivered

Site II (orange) was similar for both states but presented subtle differences, with an additional cholesterol pocket involving the Trp in extracellular loop 2 (ECL2) being more pronounced in the inactive versus the active state

Patients on tirzepatide lost an average of 20.2% of their body weight over 72 weeks Patients on semaglutide lost an average of 13.7% of their body weight over the same period 47% more tirzepatide patients achieved 25% or greater body weight loss compared to semaglutide Tirzepatide also produced greater reductions in waist circumference across all dose comparisons A 2024 meta-analysis published in JAMA Internal Medicine analyzing real-world data from over 140,000 patients confirmed the same pattern: tirzepatide produced an average of 4.23 kg more weight loss than semaglutide across all doses and durations studied

Recognizing obesity as a medical condition rather than a cosmetic issue is essential to ensuring equitable access

Hitherto, weight loss is the only intervention proven to be significantly beneficial for NAFLD patients 8

Due to the high cost and significant side effects of these medications, many studies show that more than half of patients have stopped them by the 12th month